CureVac N.V. (NasdaqGM: CVAC)
Health Care · Biotechnology · DE
$—
-0.21% today · — 1Y
CureVac N.V. (NasdaqGM: CVAC) operates in the Biotechnology industry within the Health Care sector.
trading between 4.00 and 5.55.
Tweenvest scores CureVac N.V. across four factors: quality 36/100, value 55/100, growth 100/100. Its strongest factor is growth.
CVAC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $83.00M
- P/E
- —
- EPS
- 0.80
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $5.55
- 52-week low
- $4.00
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 825
- Next earnings
- —
About CureVac N.V.
CureVac N.V. is a biopharmaceutical company currently in the clinical stage, specializing in creating innovative medical treatments leveraging messenger ribonucleic acid (mRNA) technology. Its portfolio encompasses various mRNA-based prophylactic vaccines. Among these is CV2CoV, an mRNA vaccine candidate addressing SARS-CoV-2, presently in Phase 1 clinical investigation. Another key candidate, CV7202, an mRNA prophylactic targeting the rabies virus glycoprotein, has successfully completed its Phase 1 clinical evaluation. Additionally, CVSQIV, aimed at influenza, is also undergoing Phase 1 clinical trials. Further vaccine development efforts are directed towards lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and a universal influenza solution. Beyond its vaccine initiatives, CureVac is also engaged in developing RNA-based immunotherapies for cancer. For instance, CV8102, an immunotherapy, is currently undergoing Phase 1 trials for the treatment of cutaneous melanoma, adenoidcystic carcinoma, and squamous cell carcinoma affecting the skin, head, and neck. The company was established in 2000 and operates from its main office in Tübingen, Germany.
- ISIN
- NL0015436031
- Founded
- 2000
- Listed since
- Aug 14, 2020
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.95 | -0.00% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.21 | +0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.27 | +0.10% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.98 | -0.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $824.97 | -1.09% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $138.15 | -4.77% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.